DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ktjjr4/pharmapoint_hiv) has announced the addition of the "PharmaPoint: HIV - Japan Drug Forecast and Market Analysis to 2022" report to their offering.
Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals.
Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission.
The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Japan
Key Topics Covered:
1.List of Tables/List of Figures
2. Introduction
3. Disease Overview
3.1 Etiology and Pathophysiology
3.2 Symptoms
4. Disease Management
4.1 Treatment Overview
4.2 Japan
5. Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
6. Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs Gap Analysis
6.3 Opportunities
7. Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Cobicistat
7.2.2 Elvitegravir
7.2.3 Dolutegravir
7.2.4 572-Trii
7.2.5 Quad 2
8. Market Outlook
8.1 Japan
9. Appendix
Companies Covered:
- Atripla
- Complera
- Epzicom
- Isentress
- Kaletra
- Norvir
- Prezista
- Reyataz
- Stribild
- Truvada
For more information visit http://www.researchandmarkets.com/research/ktjjr4/pharmapoint_hiv
